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What is Genomics?
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CDC works to integrate human genome knowledge into public 
health research, policy, and programs. Through the Office 
of Public Health Genomics (OPHG), CDC strives to improve 
interventions designed to prevent disease and improve the 
public’s health by
Conducting population-based genomics research.•	
Assessing the role of family health history.•	
Supporting the evaluation of genetic tests.•	
Translating genomic knowledge.•	
Conducting Population-Based Genomics Research
Population-based genomics research examines the role that 
genetic differences play on disease risk and helps to identify 
associations between genes and factors such as diet and environ-
mental exposures. These studies may help us understand which 
populations are more susceptible to disease, as well as help 
us improve their health and treatment outcomes. Examples 
of OPHG research include
 In 2008, OPHG reported genetic prevalence estimates •	
by age, sex, and race/ethnicity among non-Hispanic whites, 
non-Hispanic blacks, and Mexican Americans in a nationally 
representative sample of the U.S. population collected from 
participants in the Third National Health and Nutrition 
Examination Survey (NHANES III). These estimates provide 
the foundation for a comprehensive data bank of human 
genetic variation, which can be used as a reference for future 
population-based genomic studies.
 OPHG provides funding to other CDC programs to •	
integrate genomics into their public health studies. New 
projects funded in 2008 will examine the role of genetics and 
genomics in autism, maternal and child health, hearing loss, 
and chronic beryllium disease (a disease primarily affecting 
the lungs, caused by exposure to beryllium, a metal found 
in coal, oil, certain rock minerals, and soil).
OPHG tools for researchers include
 HuGE Navigator•	 , an up-to-date knowledge base in human 
genome epidemiology, with information on population 
prevalence of genetic variants, gene-disease associations, 
gene-gene and gene-environment interactions, and evalua-
tion of genetic tests. The HuGE Navigator contains more 
than 30,000 scientific articles on human genome epidemiol-
ogy (http://www.hugenavigator.net).
 HuGE Reviews•	 , systematic reviews of research findings 
on particular gene-disease associations, which are published 
in partnership with 10 scientific journals. These reviews 
typically point to gaps in existing epidemiologic and clinical 
Genomics is the study of all the genes in a person, as well as the 
interactions of those genes with each other and a person’s envi-
ronment. All people are 99.9% identical in genetic makeup, but 
differences in the remaining 0.1% hold important clues about 
health and disease. The study of genomics is likely to help 
doctors and other health care professionals understand why 
some people get sick from certain infections, environmental 
factors, and behaviors while others do not. This information 
could lead to new and better ways to improve health and 
prevent diseases for individuals and populations.
Public health genomics is a multidisciplinary field focused 
on the effective and responsible translation of genome-based 
knowledge and technologies into health care practices to 
improve population health. It uses population data on genetic 
variation and gene-environment interactions to develop 
evidence-based tools for improving health and preventing disease.
“Translating the knowledge we are gaining from gene discoveries 
into practical clinical and public health applications will 
be critical for realizing the potential of personalized health 
care and improving the health of the nation.”
Muin J. Khoury, MD, PhD 




knowledge, thus stimulating further research in these areas. 
In 2008, four HuGE reviews were published. Thirteen 
HuGE reviews are anticipated in 2009 on genetic risk factors 
and pregnancy and childbirth, mental disorders and epilepsy, 
lung cancer, and general cancer risk.
 HuGENet™•	 , a global collaboration of investigators around 
the world. Genomics researchers can become involved by 
undertaking systematic reviews and participating in meetings 
and workshops.
Assessing the Role of Family Health History
Family history reflects an individual’s genes and the behaviors 
and environmental factors they share with their family members. 
Family history is a risk factor for many chronic diseases, such 
as cancer, coronary heart disease, and diabetes, making it an 
important tool for identifying people at increased risk for these 
diseases. OPHG research and projects include
 A study using the Family Healthware™ tool, in which •	
researchers examined whether personalized prevention 
messages tailored to familial risk motivates people to change 
their behaviors and lifestyle and seek additional medical 
advice or screening. The methods and results of this study 
will be published in early 2009.
 A national working group on family history, which is part of •	
the U.S. Department of Health and Human Services’ (HHS) 
Personalized Health Care initiative. OPHG is helping to 
develop a plan to enable consumers to electronically and 
securely share their family health history information with 
family members and health care providers, and ultimately, 
to allow this information to become part of the consumer’s 
electronic health record.
Supporting the Evaluation of Genetic Tests
Genetic tests for more than 1,600 diseases have been developed, 
and clinical testing for more than 1,300 diseases is currently 
available. Most are used for diagnosis of rare genetic disorders, 
but a growing number of tests may help with screening for 
and prevention of chronic diseases. Based on reports of the 
HHS Secretary’s Advisory Committee on Genetics Health and 
Society, reliable, objective information is needed on genetic tests 
to help health care providers, consumers, and policy makers 
make decisions on their appropriate use. These reports support 
OPHG’s systematic and evidence-based process for evaluating 
genetic tests. OPHG-supported activities include
 •	In 2008, the independent Evaluation of Genomics Applica-
tions in Practice and Prevention (EGAPP) Working Group 
published their methods for collecting, analyzing, and 
grading evidence used to evaluate the analytic and clinical 
validity and clinical utility of genetic and genomic tests.
 In January 2009, the independent EGAPP Working Group •	
released the following three new evidence-based recom-
mendations based on EGAPP-commissioned, CDC-funded 
evidence reports:
 DNA Testing Strategies Aimed at Reducing Morbidity and  º
Mortality from Lynch Syndrome.
 Can UGT1A1 Genotyping Reduce Morbidity and Mortality  º
in Patients with Metastatic Colorectal Cancer Treated with 
Irinotecan?
 Can Tumor Gene Expression Profiling Improve Outcomes  º
in Patients with Breast Cancer?
Translating Genomic Knowledge
Translation of genomic knowledge into health practice involves 
a multidisciplinary approach. Understanding the validity, 
utility, and use of genomic information and applications will 
help guide the development of health interventions that 
maximize health benefits and minimize harm to individuals and 
populations. OPHG-supported activities include
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CDC’s Response (continued)
 State health departments in Michigan, Minnesota, Oregon, •	
and Utah completed their 5-year genomics cooperative 
agreements in July 2008. The states integrated genomics 
goals and activities into cancer control plans and helped 
establish family history assessments as part of disease preven-
tion efforts for cancer, cardiovascular disease, and diabetes. 
Through population-based surveys, the states gained knowl-
edge about consumer awareness and use of family history in 
disease prevention and of direct-to-consumer (DTC) genetic 
tests. For example, the results of a 2006 Behavioral Risk 
Factor Surveillance System (BRFSS) survey in Michigan, 
Oregon, and Utah published in 2008 showed that 24.4% 
of Oregon consumers, 19.7% of Utah consumers, and 7.6% 
of Michigan consumers were aware of DTC nutrigenomic 
tests. Older individuals up to 65 years and those with more 
education and higher income were more likely to be aware 
of these tests.
 In 2008, OPHG funded five new projects that translate •	
promising genomic applications, such as genetic tests and 
family history, into medical and public health practice. These 
projects will assess the impact of these applications on popu-
lation health. These projects include
 Family history education to improve genetic risk assess- º
ment for cancer.
 Promotion of best practices for cancer genomics through  º
surveillance, education, and policy.
 Pharmacogenomics education to bridge the gap between  º
science and practice.
 Translation of genomics applications into health practice  º
in Oregon.
 Development and evaluation of a risk-benefit framework  º
for new genetic tests to educate clinicians, policy makers, 
and other key decision makers about the potential benefits 
and harms of genetic testing.
 In 2009, the OPHG-sponsored EGAPP Stakeholders •	
Group will help to translate and disseminate the new 
EGAPP recommendations for use in clinical and public 
health practice. This group also is helping to increase aware-
ness of the EGAPP initiative and its methods and processes.
 Genomics centers at the Universities of Michigan and •	
Washington continue to provide expertise and technical 
assistance for national and state efforts to help translate 
genomic information and applications, including the 
EGAPP recommendations, into public heath research, 
policy, and programs.
 In 2008, OPHG used two national surveys to assess U.S. •	
consumer awareness and use of direct-to-consumer personal 
genome scans (HealthStyles) and knowledge of and experi-
ences with these scans among U.S. physicians (DocStyles). 
Preliminary analyses of these data indicate that one in five 
consumers surveyed were aware of these tests, but very few 
had actually used them. OPHG also worked with three state 
health departments to assess U.S. consumer awareness and 
use of these scans using the 2009 BRFSS.
Additional projects on cancer genomics have been funded 
by the National Cancer Institute (NCI) in 2009.
Future Directions
In 2009, OPHG will continue to strengthen its genomics 
translation initiative by establishing a network of government 
agencies, academic and research institutions, health care plans, 
consumer advocacy groups, biotechnology industries, and other 
organizations around common goals for using genomics in 
preventing disease, improving treatments, and reducing health 
disparities. OPHG is also more effectively using public-private 
partnerships in evaluating genetic tests. Additionally, OPHG 
will support more extensive genotyping, which will expand the 
human genetic variation data bank and make these data more 
accessible to the scientific research community.
